Mark de Souza, Ph.D.
Co-Founder and Executive Chairman
Dr. de Souza has deep experience in creating and developing virtual biotechnology companies. He has participated as a CEO/Executive Chairman/Co-Founder of NFlection Therapeutics, Chromaderm, SeylanMed, PellePharm, MyoTherix, Lotus Tissue Repair, BridgeBio companies, others. Mark has spent 15+ years in the rare disease, neurology and dermatology spaces.
Matthew Tindall, MBA
Co-Founder, President and Chief Executive Officer
Mr. Tindall has extensive entrepreneurial management experience as a CEO/Executive/Co-Founder of healthcare companies in the rare disease, oncology, pain, cardiovascular and genomics spaces with Fabric Genomics, Kodikaz, Wheatsheaf Group, IQVIA, Digitas Health, Genzyme Corporation, Celera Genomics, Eli Lilly & Company and Sarentis Therapeutics.
Curtis Scribner, MD, MBA
Co-Founder, Chief Medical Officer and Head of Clinical and Regulatory
Dr. Scribner is a board-certified internist with 25+ years experience in drug development as a clinical investigator, regulatory reviewer, and product life cycle consultant, including senior positions at the CDC and FDA Center for Biologic Evaluation and Research. He has served as a consultant to biotechnology companies working on everything from discovery and preclinical models through clinical trials, Data Safety Monitoring Committees and regulatory interactions in the US and Europe, including as Chief Regulatory Officer of Intarcia and in medical and regulatory positions at several BridgeBio companies.
Jay Rajadas, PhD
Co-founder & Scientific Advisor
Dr. Rajadas is the Director, Stanford Medicine BioADD, Assistant Director of CV Pharmacology and a Member of the Stanford Lyme Disease Working Group. He is also Adjunct Professor, Department of Bioengineering and Therapeutic Sciences. University of California San Francisco (UCSF) School of Pharmacy. Jay is an avid inventor and prolific scientist with more than 217 publications and 10s of patents. Dr. Rajadas received his M.S. in Chemistry from University of Madras and Ph.D. in Biophysical Chemistry from Indian Institute of Technology.
Monica Embers, PhD
Dr. Embers is an Assistant Professor Microbiology & Immunology, School of Medicine at Tulane University. Her focus has been on bacterial pathogenesis since her postdoctoral research on the Lyme disease spirochete and leads the Tulane National Primate Research Center (TNPRC). Her research program regarding Borrelia burgdorferi and Lyme disease is designed around three major foci: (1) evaluating antibiotic efficacy against Lyme disease; (2) identifying treatments that can eradicate B. burgdorferi infection; and (3) immunodiagnosis for B. burgdorferi infection and cure.